Sohal Aalam, Thind Nuhar, Billing Harbir Singh, Iqbal Humzah, Menon Rohan, Kumar Vikash, Sohal Aalam, Yang Juliana
Department of Internal Medicine, Tristar Centennial Medical Center, Nashville, TN, USA.
Dayanand Medical College and Hospital, Punjab, India.
J Gastrointestin Liver Dis. 2025 Jun 28;34(2):220-226. doi: 10.15403/jgld-6066.
Cannabis is a commonly used recreational and medicinal substance and has been shown to have anti-inflammatory and analgesic effects. Previous studies have shown that cannabis may reduce disease severity of pancreatitis. We aim to use nationally available data to further investigate the impact of cannabis on outcomes among patients with chronic pancreatitis (CP).
Nationwide Inpatient Sample (NIS) 2016-2020 was used to identify patients with CP. Patients were stratified based on the presence of cannabis use. Data was collected regarding patient demographics, comorbidities, and Charlson Comorbidity Index (CCI). The outcomes assessed were sepsis, acute kidney injury (AKI), deep vein thrombosis (DVT), pulmonary embolism (PE), intensive care unit (ICU) admission, acute pancreatitis (AP), pancreatic cancer, total charges, and length of stay. The relationships were analyzed using multivariate logistic regression.
Out of 907,790 hospitalized patients in this study; 52,360 (5.8%) were cannabis users. After adjusting for confounding factors, cannabis use was associated with decreased odds of mortality (aOR=0.47, p<0.001), DVT (aOR=0.71, p<0.001), PE (aOR=0.622, p=0.002), ICU admission (aOR=0.705, p<0.001), pancreatic cancer (aOR=0.730, p=0.021). There was no difference in odds of AKI, sepsis or AP between the two groups.
Our study found that cannabis use is associated with reduced disease severity and better outcomes among patients hospitalized with CP. Further studies are needed to confirm our findings and explore the role of cannabinoids in pancreatitis.
大麻是一种常用的消遣和药用物质，已显示具有抗炎和镇痛作用。先前的研究表明，大麻可能会降低胰腺炎的疾病严重程度。我们旨在利用全国可得的数据，进一步研究大麻对慢性胰腺炎（CP）患者预后的影响。
使用2016 - 2020年全国住院患者样本（NIS）来确定CP患者。根据是否使用大麻对患者进行分层。收集了有关患者人口统计学、合并症和查尔森合并症指数（CCI）的数据。评估的结局包括败血症、急性肾损伤（AKI）、深静脉血栓形成（DVT）、肺栓塞（PE）、重症监护病房（ICU）入院、急性胰腺炎（AP）、胰腺癌、总费用和住院时间。使用多因素逻辑回归分析这些关系。
在本研究的907,790名住院患者中，52,360名（5.8%）是大麻使用者。在调整混杂因素后，使用大麻与死亡率降低（调整后比值比[aOR]=0.47，p<0.001）、DVT（aOR=0.71，p<0.001）、PE（aOR=0.622，p=0.002）、ICU入院（aOR=0.705，p<0.001）、胰腺癌（aOR=0.730，p=0.021）的几率降低相关。两组之间AKI、败血症或AP的几率没有差异。
我们的研究发现，使用大麻与CP住院患者的疾病严重程度降低和更好的预后相关。需要进一步的研究来证实我们的发现，并探索大麻素在胰腺炎中的作用。
